samedan logo
 
 
 
spacer
home > ebr > autumn 2002 > over the counter and through the woods: china's otc market in transition
PUBLICATIONS
European Biopharmaceutical Review

Over the Counter and Through the Woods: China's OTC Market in Transition

Winters in Shanghai can be particularly tough - cold grey days marked with heavy wind and rain. In a crowded city of 16 million, there are likely to be lots of colds and flu, and much like anywhere these sufferers will want fast and effective relief. Unless symptoms are severe, most Chinese will look to prescription-free OTC drugs purchased from a retail pharmacy, to ease their pain. This article looks at factors which signal growth in this sector, current obstacles and barriers which might preclude foreign participation and what changes are afoot to allow for a more open and competitive market.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Ben Goodger, Head of the Asia Commercial Intellectual Property Group at Rouse & Co, Shanghai

Ben Goodger is an Executive of Rouse & Co International, specialists in intellectual property management and protection worldwide. Ben won an Open Exhibition to Keble College in 1981 and completed his Articles with Frere Cholmeley Bischoff. After qualification, he joined the city law firm of Denton Hall.
In 1993 he joined Dallas Brett and was made a Partner in 1996, before moving to Rouse & Co/Willoughby & Partners in 1997. His practice can broadly be split into three main areas: computers and Internet related law, 'hi-tech' (biotechnology, technology transfer, patents) and trademark protection/brand management. He re-located to Rouse & Co's Shanghai office in August 2002 to head up the firm's Asia Commercial Intellectual Property Group.

spacer
Ben Goodger
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

First own Gerresheimer Autoinjector - Gerresheimer and Midas Pharma announce strategic partnership

– Gerresheimer’s first own IP autoinjector suitable for both small and large molecules enhances broad portfolio of solutions, medical devices and pharmaceutical primary packaging – First joint project of Gerresheimer and Midas Pharma: Development and marketing of new autoinjector – One-stop-shop for biotech and pharma customers Duesseldorf, November 08, 2021 – Gerresheimer acquired the IP of a new generation cartridge based autoinjector from Midas Pharma. This is the start of a strategic partnership. The joint project comprises the development and marketing of the new generation autoinjector.
More info >>

White Papers

The Power of Execution in Clinical Research

Medpace

Medpace, long known for its excellence in conducting Phase I-IV studies on a global platform, is particularly noted for its therapeutic excellence. When that expertise is combined with operational precision, the results are nothing short of stellar. The Medpace full-service outsourcing approach – combined with therapeutic expertise, regulatory know how, and global presence – delivers clinical studies with an industry recognized track record.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement